Breast Cancer Biomarkers: The Emerging Role of Immune and Digital Biomarkers and the Benefits of Parallel CDx Development

How do you identify the right patient for a given drug? How do you select your population to ensure that the signal of benefit is most pronounced? The boundaries of breast cancer biomarker development are being increasingly pushed to help power better decisions for developers, oncologists and, ultimately, for breast cancer patients. Learn about the emerging role of immune and digital biomarkers, and the benefits of parallel development of therapeutics and CDx.